Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Thrombosis and Thrombolysis
Erschienen in: Journal of Thrombosis and Thrombolysis 3/2021

14.09.2021 | COVID-19 Zur Zeit gratis

Immature platelets in patients with Covid-19: association with disease severity

verfasst von: Amir Cohen, Emanuel Harari, Ella Yahud, Michal Cipok, Gabriel Bryk, Nili Karp Lador, Tal Mann, Ami Mayo, Eli I. Lev

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Coronavirus disease 2019 (Covid-19) is associated with a high incidence of venous and arterial thromboembolic events. Currently, there are no clinical or laboratory markers that predict thrombotic risk. Circulating immature platelets are hyper-reactive platelets, which are associated with arterial thrombotic events. The aim of this study was to assess whether the proportion of circulating immature platelets is associated with disease severity in Covid-19 patients. Patients admitted with Covid-19 disease were prospectively assessed. Immature platelet count (IPC) and immature platelet fraction (IPF) were measured at admission and at additional time points during the hospital course using the Sysmex XN-3000 auto-analyzer. A total of 136 consecutive patients with Covid-19 were recruited [mean age 60 ± 19 years, 49% woman, 56 (41%) had mild-moderate disease and 80 (59%) had severe disease at presentation]. The median IPF% was higher in patients with severe compared to mild-moderate disease [5.8 (3.9–8.7) vs. 4.2 (2.73–6.45), respectively, p = 0.01]. The maximal IPC value was also higher in patients with severe disease [15 (10.03–21.56), vs 10.9 (IQR 6.79–15.62), respectively, p = 0.001]. Increased IPC was associated with increased length of hospital stay. Patients with severe Covid-19 have higher levels of IPF than patients with mild-moderate disease. IPF may serve as a prognostic marker for disease severity in Covid-19 patients.
Literatur
1.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507–513CrossRef
2.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet 395(10223):497–506CrossRef
3.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan China. JAMA 323(11):1061–1069CrossRef
4.
Boonyawat K, Chantrathammachart P, Numthavaj P, Nanthatanti N, Phusanti S, Phuphuakrat A, Niparuck P, Angchaisuksiri P (2020) Incidence of thromboembolism in patients with Covid-19: a systematic review and meta-analysis. Thromb J 18(1):34CrossRef
5.
Zhang L, Feng X, Zhang D, Jiang C, Mei H, Wang J, Zhang C, Li H, Xia X, Kong S et al (2020) Deep vein thrombosis in hospitalized patients with Covid-19 in Wuhan, China: prevalence, risk factors, and outcome. Circulation 142(2):114–128CrossRef
6.
Dubois-Silva Á, Barbagelata-López C, Mena Á, Piñeiro-Parga P, Llinares-García D, Freire-Castro S (2020) Pulmonary embolism and screening for concomitant proximal deep vein thrombosis in noncritically ill hospitalized patients with coronavirus disease 2019. Intern Emerg Med 15(5):865–870CrossRef
7.
Mestre-Gómez B, Lorente-Ramos RM, Rogado J, Franco-Moreno A, Obispo B, Salazar-Chiriboga D, Saez-Vaquero T, Torres-Macho J, Abad-Motos A, Cortina-Camarero C, Infanta Leonor Thrombosis Research Group (2021) Incidence of pulmonary embolism in non-critically ill Covid-19 patients. Predicting factors for a challenging diagnosis. J Thromb Thrombolysis 51(1):40–46CrossRef
8.
Shang W, Dong J, Ren Y, Tian M, Li W, Hu J, Li Y (2020) The value of clinical parameters in predicting the severity of Covid-19. J Med Virol 92(10):2188–2192CrossRef
9.
Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW et al (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395(10223):514–523CrossRef
10.
Lippi G, Plebani M, Henry BM (2020) Thrombocytopenia is associated with severe coronavirus disease 2019 (Covid-19) infections: a meta-analysis. Clin Chim Acta 506:145–148CrossRef
11.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al (2020) Clinical course and risk factors for mortality of adult inpatients with Covid-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062CrossRef
12.
Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844–847CrossRef
13.
Lev EI (2016) Immature platelets: clinical relevance and research perspectives. Circulation 134(14):987–988CrossRef
14.
Hille L, Lenz M, Vlachos A, Grüning B, Hein L, Neumann FJ, Nührenberg TG, Trenk D (2020) Ultrastructural, transcriptional, and functional differences between human reticulated and non-reticulated platelets. J Thromb Haemost 18(8):2034–2046CrossRef
15.
Bernlochner I, Goedel A, Plischke C, Schüpke S, Haller B, Schulz C, Mayer K, Morath T, Braun S, Schunkert H et al (2015) Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. Eur Heart J 36(45):3202–3210CrossRef
16.
Freynhofer MK, Gruber SC, Grove EL, Weiss TW, Wojta J, Huber K (2015) Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Thromb Haemost 114(3):459–468PubMed
17.
Pons I, Monteagudo M, Lucchetti G, Muñoz L, Perea G, Colomina I, Guiu J, Obiols J (2010) Correlation between immature platelet fraction and reticulated platelets Usefulness in the etiology diagnosis of thrombocytopenia. Eur J Haematol 85(2):158–163PubMed
18.
Cohen A, Harari E, Cipok M, Laish-Farkash A, Bryk G, Yahud E, Sela Y, Lador NK, Mann T, Mayo A et al (2021) Immature platelets in patients hospitalized with Covid-19. J Thromb Thrombolysis 51(3):608–616CrossRef
19.
Lenz, Maximilian, et al. Covid-19 Treatment guidelines panel. Coronavirus Disease 2019 (Covid-19) Treatment Guidelines. National Institutes of Health
20.
Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, Navalesi P, Simioni P (2020) Covid-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 120(6):998–1000CrossRef
21.
Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, Ibrahim H, Friedman GH, Thompson C, Alviar CL et al (2020) ST-segment elevation in patients with Covid-19—a case series. N Engl J Med 382(25):2478–2480CrossRef
22.
Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, De Leacy RA, Shigematsu T, Ladner TR, Yaeger KA et al (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 382(20):e60CrossRef
23.
Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M, Metra M, Curello S, Maffeo D, Pero G et al (2020) ST-elevation myocardial infarction in patients with Covid-19: clinical and angiographic outcomes. Circulation 141(25):2113–2116CrossRef
24.
Cesari F, Marcucci R, Gori AM, Caporale R, Fanelli A, Casola G, Balzi D, Barchielli A, Valente S, Giglioli C et al (2013) Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study. Thromb Haemost 109(5):846–853CrossRef
25.
Martin JF, Kristensen SD, Mathur A, Grove EL, Choudry FA (2012) The causal role of megakaryocyte–platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol 9(11):658–670CrossRef
26.
Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD (2011) Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 9(1):185–191CrossRef
27.
López-Jiménez RA, Martín-Herrero F, González-Porras JR, Sánchez-Barba M, Martín-Luengo C, Pabón-Osuna P (2013) Immature platelet fraction: a new prognostic marker in acute coronary syndrome. Rev Esp Cardiol 66(2):147–148CrossRef
28.
Gonzalez-Porras JR, Martin-Herrero F, Gonzalez-Lopez TJ, Olazabal J, Diez-Campelo M, Pabon P, Alberca I, San Miguel JF (2010) The role of immature platelet fraction in acute coronary syndrome. Thromb Haemost 103(1):247–249CrossRef
29.
Grove EL, Hvas AM, Kristensen SD (2009) Immature platelets in patients with acute coronary syndromes. Thromb Haemost 101(1):151–156CrossRef
30.
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A et al (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 383(2):120–128CrossRef
31.
Bunce PE, High SM, Nadjafi M, Stanley K, Liles WC, Christian MD (2011) Pandemic H1N1 influenza infection and vascular thrombosis. Clin Infect Dis 52(2):e14–e17CrossRef
32.
Rondina MT, Brewster B, Grissom CK, Zimmerman GA, Kastendieck DH, Harris ES, Weyrich AS (2012) In vivo platelet activation in critically ill patients with primary 2009 influenza A(H1N1). Chest 141(6):1490–1495CrossRef
33.
Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, Liu M, Zhao X, Xie Y, Yang Y et al (2020) SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in Covid-19. J Hematol Oncol 13(1):120CrossRef
Metadaten
Titel
Immature platelets in patients with Covid-19: association with disease severity
verfasst von
Amir Cohen
Emanuel Harari
Ella Yahud
Michal Cipok
Gabriel Bryk
Nili Karp Lador
Tal Mann
Ami Mayo
Eli I. Lev
Publikationsdatum
14.09.2021
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 3/2021
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-021-02560-x

Weitere Artikel der Ausgabe 3/2021

Journal of Thrombosis and Thrombolysis 3/2021 Zur Ausgabe

OriginalPaper

Wirkung einer tPA-induzierte Fibrinolyse bei COVID-Patienten eingeschränkt?

OriginalPaper

Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series

OriginalPaper

Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure

OriginalPaper

Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral Factor Xa inhibitors

OriginalPaper

The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials

Correction

Correction to: Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation

Passend zum Thema

ANZEIGE

Bei Immuntherapien das erhöhte Thromboserisiko beachten

Unter modernen Systemtherapien versechsfacht sich das VTE-Risiko. Warum diese Daten relevant für die Behandlung krebsassoziierter Thrombosen sind, erläutert Prof. F. Langer im Interview. So kann es durch Immuntherapien zu inflammatorischen Syndromen z.B. im GI-Trakt kommen. Nebenwirkungen wie Durchfall oder Mukositis haben dann Einfluss auf die Wirksamkeit oraler Antikoagulantien. Aber auch in punkto Blutungsrisiko ist Vorsicht geboten. Wann hier bevorzugt NMH eingesetzt werden sollten, erläutert Prof. Langer im Interview.

ANZEIGE

CAT-Management ist ganz einfach – oder doch nicht?

Krebsassoziierte venöse Thromboembolien (CAT) haben in den vergangenen Jahren stetig zugenommen. Was hat der Anstieg mit modernen Antitumortherapien zu tun? Venöse Thromboembolien sind relevante Morbiditäts- und Mortalitätsfaktoren in der Onkologie. Besonders hoch sind die Risiken bei Tumoren des Abdominalraums. Eine antithrombotische Primärprophylaxe ist daher gerade bei gastrointestinalen (GI-) Tumoren auch im ambulanten Setting wichtig.

ANZEIGE

Management von Thromboembolien bei Krebspatienten

Die Thromboembolie ist neben Infektionen die zweithäufigste Todesursache bei Krebspatienten. Die Behandlung der CAT (cancer associated thrombosis) ist komplex und orientiert sich am individuellen Patienten. Angesichts einer Vielzahl zur Verfügung stehender medikamentöser Behandlungsoptionen finden Sie hier Video-Experteninterviews, Sonderpublikationen und aktuelle Behandlungsalgorithmen zur Therapieentscheidung auf Basis von Expertenempfehlungen.

LEO Pharma GmbH

Weitere Lesetipps

Darmvorbereitung vor Rektumresektion ab jetzt kombiniert?

ANZEIGE

CAT: Was tun bei Lücken in der Evidenz

Interdisziplinäre Behandlungsstrategien bei Hirnmetastasierung

ANZEIGE

Spagat zwischen Leitlinien und klinischem Alltag

ANZEIGE

Herausforderungen und Management krebsassoziierter Thrombosen

Wie Immuntherapieresistenz überwinden? Auf der Suche nach dem X

Bildnachweise